EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update by A. Iolascon et al.
Powered by EHA
Review ArticleEHA Research Roadmap on Hemoglobinopathies
and Thalassemia: An Update
Achille Iolascon1, Lucia De Franceschi2, Martina Muckenthaler3, Ali Taher4, David Rees5,
Mariane de Montalembert6,7, Stefano Rivella8, Androulla Eleftheriou9, Maria Domenica Cappellini10






























The inherited disorders of hemoglobin, which include sickle cell disease and thalassemias, are the most common and widespread
distributed monogenic disorders. Due to a selective advantage in malaria regions, these hemoglobin defects are particularly frequent in
Africa, Asia, or in the Mediterranean areas, where malaria was endemic until the last century. In recent decades, the globalization of
migration has contributed to generate multiethnic European societies. Due to migration from countries or regions with high
hemoglobinopathy frequencies such as Africa, Middle East, or Asia, large numbers of patients with these disorders are living in almost
every European country today. Furthermore, the numbers are increasing because of increasing refugee ﬂows toward Europe. Additional
requirements are the development of European recommendations and guidelines for diagnosis and effective therapeutic approaches.
These, together with the advancement of clinical trials using new drugs and therapeutic procedures could ameliorate the quality of life of
patients affectedwith thesediseasesand increase their life expectancy.Lastly, coordinatedefforts shouldbemade todevelopdiagnostic
pathways for thalassemias and hemoglobinopathies, in order to plan interventions, including prenatal diagnosis and cure. For these
reasons, the development of new tools to reliably diagnose anemias is urgently needed and ﬁts well with the needs of personalized
medicine. In the last 15 years, hematology research has made many big leaps forward. Our general aim will be to solve several
hematologic problems using these new approaches. We expect that the development of such a diagnostic tool will improve timely
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1hemoglobin (Hb), which include sickle cell disease and
thalassemias, are the most common and widespread distributed
monogenic disorders1–5 (Table 1). Due to a selective advantage in
malaria regions, these Hb defects are particularly frequent in
Africa, Asia or in the Mediterranean areas, where malaria was
endemic until the last century.1–4
In recent decades, the globalization ofmigration has contributed
to generate multiethnic European societies. According to the
Organization for Economic Co-operation and Development
(OECD), the percentage of the foreign-born population within
the European Community in 2008 ranged from 4% in Finland to
37% in Luxembourg, with an overall average of 8%.6 Due to
migration from countries or regions with high hemoglobinopathy
frequencies such as Africa, Middle East, or Asia, large numbers of
patients with these disorders are living in almost every European
country today. Furthermore, the numbers are increasing because of
increasing migrant ﬂows toward Europe.
Thus, it is important for health care systems to investigate and
ensure that they can adequately address the many and complex
lifelong needs of these patients.Moreover, the absence of national
registries and prevention programs in the great majority of these
countries makes it essential to identify ways and tools to better
describe the extent of the problem in terms of numbers and
distribution across each country in order to deal with the medical
needs of patients with severe, chronic and disabling disorders
such as hemoglobinopathies, considering the insufﬁcient level of
knowledge of medical teams who are now having to take care of
these patients. This will map the distribution of the different
forms of hemoglobinopathies in each European country and help
Table 1
Synopsis of Most Common Diseases Associated With Mutations in the Globin Beta Gene (HBB)
Adult hemoglobin (HbA) consists of globin alpha (encoded by the HBA1 and HBA2 genes) and globin beta (encoded by the HBB gene). Worldwide distribute monogenic
disorders are related to mutations on either beta or alpha globin genes
Sickle cell disease (OMIM: 603903)
Sickle-cell disease (SCD) is a monogenic disorder but a multiorgan disease. The pathologic HbS characterizes SCD. The main clinical presentations are chronic hemolysis and
acute vaso-occlusive crisis, which recurrence results in progressive organ damage
In Europe, the prevalence of HbS carriers is 1/150 and 1–5/10,000 affected newborns
Treatment: Hydroxyurea is the standard treatment for children and adults with SCD. Regular or occasional transfusions as either classic transfusion or exchange is an
additional therapeutic strategy in clinical management of both acute and chronic SCD related organ damage. Bone marrow transplantation should be considered as curative
option in presence of an HLA matching donor
b-Thalassemia (OMIM: 613985)
b-Thalassemia is characterized by a reduced production of reduced or absent production of globin beta with accumulation of alpha-free chains
In Europe, the incidence of symptomatic individuals is estimated at 1 in 10,000
Clinical presentation allows the identiﬁcation of thalassemia transfusion-dependent thalassemia (TDT) and nontransfusion-dependent thalassemia (NTDT), mainly represented
by patients with b-thalassemia intermedia. Carriers of thalassemia are deﬁned also as thalassemia minor, who are generally asymptomatic
Treatment: Chronic transfusion of packed red cells and iron chelation therapy. Bone marrow transplantation should be considered as curative option in presence of an HLA
matching donor
A. Iolascon et al. EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Updateto plan effective health and other care including social
interventions. The development and use of national registries
is thus of pivotal signiﬁcance to allow for more accurate mapping
of patient numbers, in both space and time. With data from
registries we will develop a detailed map of patients affected by
these conditions, which is essential for planning social and health
interventions (Table 2).
Additional requirements are the development of European
recommendations and guidelines for diagnosis and effective
therapeutic approaches. These, together with the advancement of
clinical trials using new drugs and therapeutic procedures could
ameliorate the quality of life of patients affected with these
diseases and increase their life expectancy. Lastly, coordinated
efforts should be made to develop diagnostic pathways for
thalassemias and hemoglobinopathies, in order to plan inter-
ventions, including prenatal diagnosis and cure. For these
reasons, the development of new tools to reliably diagnose
anemias is urgently needed and ﬁts well with the needs of
personalized medicine. In the last 15 years, hematology research
has made many big leaps forward. For instance, the emergence of
sophisticated genetic and molecular tools (e.g., next generation
sequencing (NGS) technique) allowed spectacular progresses in
our understanding of the structure and function of the blood cells
in health and disease. We anticipate that use of these new
approaches will solve several hematologic problems.7,8 We
expect that the development of such a diagnostic tool willTable 2
Directions of Research Roadmap in Hemoglobinopathies (Tha-
lassemias and SCD)
• Epidemiology of Hb-pathies (SCD and thalassemias) in Europe: establish Europe-
wide national registries
• Common pathways for prenatal screenings, diagnosis and follow-up
• Support studies on mechanisms of Hb-pathies (SCD and thalassemias)
• Identify new therapeutic targets (e.g., such as preclinical studies on animal
models)
• Enhance clinical trials for emerging drugs and strengthen research for new drugs
• Identify speciﬁc patients needs and help to train expert-patients
• Develop PRO tools to support the work of patient organizations in better identifying
patient needs
• Strengthening and creation of hemoglobinopathy advocacy groups in each country
and once on a pan-European level to discuss and provide the patients’ perspective
and “lobbying” where necessary for change and improvements
PRO=patients reported outcomes, SCD= sickle cell disease.
2improve timely diagnosis throughout Europe, especially in those
countries where it is difﬁcult to gain access to “classical”
diagnostic tests (Table 2).Hemoglobinopathies: Sickle cell disease
Background: Sickle cell disease (SCD) is a worldwide hereditary
red cell disorder caused by a point mutation in the b-globin gene.
This results in the synthesis of pathological hemoglobin S (HbS),
which displays peculiar biochemical characteristics, polymerizing
under deoxygenation.9,10 SCD is a chronic and disabling
disorder, associated with highmorbidity andmortality. Although
signiﬁcant numbers of patients with sickle cell disease have lived
in Europe for many decades (Greece, Turkey, UK, France,
Germany, Italy), in the last two decades, due to immigration
ﬂuxes from endemic areas, SCD has increased in prevalence
throughout Europe. Presently, the estimated prevalence of
affected newborns and SCD carriers in Europe are approximately
1 to 5/10,000 and 1/150, respectively. However, epidemiological
predictions suggest an increasing global burden of SCD between
2010 and 2050, making SCD an emerging problem of public
health with limited therapeutic options. Hydroxycarbamide
(HC) therapy and the comprehensive care provided throughout
life, from childhood to adulthood have signiﬁcantly increased the
survival of these patients in childhood, but has probably had less
impact on adult morbidity and mortality.11–14
Past achievements in Europe: In the last decades, pathophysi-
ological studies have shown that dense, dehydrated red cells play
a central role in acute and chronic clinical manifestations of SCD,
in which intravascular sickling leads to vaso-occlusion and
impaired blood ﬂow with ischemic/reperfusion injury. In the
microcirculation, vaso-occlusive events (VOC) result from
complex and still partially understood mechanisms, involving
the interactions between different cell types, including dense red
cells, reticulocytes, abnormally activated endothelial cells,
leukocytes, platelets, and plasma factors. Recently the role of
proadhesion molecules such as vascular adhesion molecule-1
(VCAM-1) or selectins such as P-selectin have been shown to be
important in recruitment and adhesion of both neutrophils and
sickle red cells to the abnormally activated vascular endothelial
surface. Thus, new therapeutic agents interfering with either red
cell sickling/dehydration or adhesion to inﬂammatory activated
endothelial cells or oxidative stress have been developed.10,15,16
These results were achieved while large clinical studies,
(2019) 3:3 www.hemaspherejournal.comperformed on SCD in pediatric and adult populations, evaluated
the possibility of switching from chronic transfusions to HC in
selected subjects with previous evidence of abnormal cerebro-
vascular blood ﬂow.17
Past achievements in Europe have included the dissemination
of the knowledge on SCD in European countries; the generation
of data on the natural history of SCD after hematopoietic stem
cell transplantation; the identiﬁcation of markers to be used in
decision making process in patients with SCD and cerebrovascu-
lar disease to switch from chronic transfusion regimen to HU in
subjects with previous evidence of abnormal cerebrovascular
velocities; the successful treatment of a patient with SCD with
gene therapy18,19; the generation of clinical data on large cohorts
of SCD patients in close collaboration with African scientists and
physicians. In addition, European research has contributed to the
characterization of newmechanisms involved in the pathogenesis
of SCD as well as in the identiﬁcation of new possible therapeutic
targets using both in vitro cell-based and in vivo animal-based
approach. European research has greatly contributed to the state
of the art in the ﬁeld of SCD and to the progress in the disease
knowledge within the international scientiﬁc community.
Proposal: Although signiﬁcant progress has been made in
increasing the knowledge with regards to the natural history and
pathophysiology of SCD, its treatment is still unsatisfactory for
both acute and chronic clinical complications. Thus, future
research in SCD should face biocomplexity, requiring the support
of the European Community on both preclinical studies as well as
on clinical trials. Since SCD is an important disease in Europe, the
EU should launch dedicated grant calls and actions to support
research on SCD in Europe.
The European SCD scientiﬁc community has identiﬁed the
following 5 critical areas of action:(1) Comprehensive phenotype characterization of the large
European SCD cohort of patients, which will allow us to
get epidemiologic information; to establish a European
registry of patients; to generate both a clinical database
and bio-bank and to facilitate research into clinical manage-
ment identifying new biomarkers of disease severity and
subgroups of patients who might beneﬁt from more
personalized medicine.
Understand the impact of social, economic, and environmen-(2)
tal factors on complications of sickle cell disease, which is
particularly important in the face of climate change and poor
air quality, given that SCD predominantly affects the urban-
poor populations in most European countries.
Increase the synergy between European research teams(3)
working on pathophysiology of SCD at preclinical levels.
This will ensure the progress on the knowledge of SCD and
the exploitation of new therapeutic leads to clinical trial in the
near future.
Dissemination of the knowledge on SCD at different levels:(4)
medical school, nurse training, family doctors, nurses and
physicians working in the emergency department, hematol-
ogists, pediatricians, internal medicine doctors, and psychol-
ogists. This might generate common action at the European
level to ensure optimal care of SCD patients, who currently do
not have access to specialist clinical services in many parts of
Europe.
Early identiﬁcation of SCD in migrants, who represent(5)
marginalized and vulnerable people, exposed to extreme
conditions during their travels through Middle-East and
Africa to the coasts of Southern European countries. The3delay in the identiﬁcation of SCD may lead to severe acute
organ complications and preventable death. Thus, an action
is needed to help manage acute health problems caused by
SCD, which might dominate the ﬁrst phase of transition of
migrants. This might include the development of guidelines
and algorithms for the management of acute events in
emergency department (ED) and the dissemination of
knowledge about SCD, to emergency department physi-
cians,20 pediatricians, hematologists, and internal medicine
physicians.
Impact of proposed projects: Future European research
programs on SCDwill contribute to the progress in the knowledge
of SCD and will deliver education of health-care professionals
throughout Europe about SCD; new therapeutic options for
clinical management of SCD, including drugs developed from
preclinical studies; new proﬁling of disease severity for personal-
ized medicine; optimization of SCD patient care; clinical trials
addressing basic aspects of clinical care; improvement of early
identiﬁcation and care for refugees with SCD.
These approaches will have a positive impact by increasing the
visibilityof SCD inEurope; improvingpatient healthoutcomes and
quality of life; generating public–private partnerships for orphan
drug development largely based on innovation, generating new
opportunities in the context of international competition; attract-
ing a new generation of physicians and researchers working on
SCD; improving health systems by reductions of care costs;
reducing national andEuropeanwelfare spending ondisabilities of
SCD patients and in the level of sickness absence from jobs.
Finally, the European experience of SCD would also have an
impact on the management of SCD in other high-income
countries such as the USA, as well as low- and middle-income
countries, such as Africa and Indiawhere SCD is a very signiﬁcant
health problem.Hemoglobinopathies: b-Thalassemias
Background: b-thalassemias are a group of inherited hemoglobin
disorders that constitute major challenges to health care systems
in Europe and across the world owing to their complexity,
heterogeneity, clinical outcomes and high cost of disease and its
management (Table 1). An estimated 1% to 5% of the global
population are carriers of a b-thalassemic mutation.20 Although
the epidemiology of the various clinical forms remains unclear,
the disease is known to be highly prevalent in areas extending
from sub-Saharan Africa through the Mediterranean region and
Middle East, to the Indian subcontinent and East and Southeast
Asia. It is conservatively estimated that >40,000 babies with
b-thalassemia are born each year worldwide.21 As a consequence
of public health improvements globally and the resulting lower
childhood mortality together with population growth and the
enduring absence of effective national prevention programs, a
substantial increase in the number of affected births all over the
world is expected, and has already started. Therefore, despite
limited available epidemiological data on hemoglobinopathies in
Europe, b-thalassemia is expected to pose an increasingly severe
global burden in future years. The annual incidence of
symptomatic individuals is estimated at between 1 in 100,000
worldwide and 1 in 10,000 in Europe.21 Migrations from
endemic areas to Europe also led to rising incidence of beta-
thalassemia in large urban centers. b-thalassemic patients
experience a high burden of illness and their quality of life is
jeopardized.
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patients with b-thalassemia in recent years which now extends
beyond 40 years of age22 owing to the availability and use of
regular red blood cell (RBC) transfusion and effective iron
chelation therapy (ICT). Despite important improvements in the
management of b-thalassemia, there are still many challenges to
overcome before global disease control is achievable. For
example, screening and prevention programs in the context of
nationally coordinated programs are inadequate or nonexistent
in European countries where b-thalassemia was rare in the past
or in many resource-constrained countries, and access to effective
treatment is far from universal.23
Past achievements in Europe: Our understanding of the
underlying pathophysiological mechanisms of b-thalassemia and
its associated clinical morbidity has increased substantially in
recent years. Key milestones in optimizing management with
transfusion or iron chelation therapy (ICT) have been achieved.
Such advances in supportive management have led to signiﬁcant
improvements in survival in this once fatal disease. For example,
mortality rates in Western cohorts have declined from 12.7 to
1.65 deaths/1000 patient-years between the periods 1980 to
1999 and 1999 to 2013,21 with the leading cause of deathmoving
from iron overload and bonemarrow transplant complications to
infections and hepatitis C virus complications. European clinical
and basic research groups have largely contributed to the
development of the new oral iron chelators associated with the
improvement of the quality of thalassemia care, resulting in
improving further to health and survival patient quality of
life24,25 and almost full social integration. In addition, European
groups have also contributed to the research and development of
gene therapy strategies for b-thalassemia to address the a-globin
or b-globin chain imbalance. Gene therapy is based on the idea
that if there is a defect in the production of b-globin in
b-thalassemia, exogenous production of b-like globins could
correct the disorder. The hemopoietic system is convenient for
such approaches, since hemopoietic stem cells from an individual
with b-thalassemia can be isolated and transduced with viruses to
introduce exogenous genetic material, such as b-like globin
transgenes that can allow for such exogenous gene expression.26
Besides gene therapy, more recent approaches have been
developed to directly correct genetic mutations in the endogenous
DNA of the cell or to disrupt speciﬁc DNA sequences in the
genome. This approach is known as genome editing and has been
facilitated through the identiﬁcation of several enzymes, includ-
ing CRISPR/Cas9, that can introduce DNA breaks in speciﬁc
regions of the genome.27 The translation from benchside-to-
bedside of new agents stimulating and supporting normal,
effective erythropoiesis has also been developed (e.g., Luspa-
tercept or Sotatercept). Additional studies on erythropoiesis and
iron metabolism have led to the development of promising new
drugs that have the potential to improve erythropoiesis, prevent
or minimize splenomegaly and address iron metabolism, some of
which are already in clinical trials.28,29
Proposal: Our improved understanding of the pathophysiolo-
gy and disease burden in patients with b-thalassemia and the
signiﬁcant contribution of the educational program of the
Thalassemia International Federation (TIF), including its Guide-
lines (for prevention and management)30 have helped to optimize
disease management and to construct a plan for the development
of novel therapeutics. However, sadly these have been adopted
and/or implemented in the context of national programs in very
few countries across the world, thus calling for concentrated
international action. Nonetheless, the clinical and medical4complexity of b-thalassemia as a disease, together with major
advances in understanding the genotypic basis of the disease,
might imply the need for individualized therapy, to identify the
most appropriate treatment for each individual patient.
We propose the following ﬁve guidelines/procedures/steps to
further improve the global care of thalassemia patients:(1) Improve the treatment of immigrant populations and
refugees, through increasing awareness among patients and
caregivers in European and other countries where thalassemia
was not a health priority but is now more common due to
migration and refugee ﬂows of people from countries with
high hemoglobinopathy prevalence.
Promote patients reported outcomes (PRO). Understanding(2)
the degree of patient-perceived health impairment is essential
to determine the burden of illness of b-thalassemia and to
recommend suitable therapy. Patient reported outcomes
(PROs), including QoL, are considered an important aspect
of effective health care in b-thalassemia, as in every chronic
disease. Further, PROs have been increasingly recognized as
critical to understanding the burden of disease and treatment
efﬁcacy by both regulatory agencies and health technology
assessment bodies. One step could be to document the burden
of illness (deﬁned as impairment of quality of life, QoL) in
nontransfusion-dependent and transfusion-dependent thal-
assemia patients receiving standard care in Europe with a
focus on patient-reported physical, mental, and social
impairment in QoL.
Support the development and implementation of new safe and(3)
effective therapeutic approaches, including gene therapy,
genome editing and targeting the alpha and beta globin chain
imbalance to reduce ineffective erythropoiesis. To improve this
important ﬁeld, there is a need to sustain research with
adequate funding (grant calls favoring translational research).
Implement the activities of European networks (i.e., Euro-(4)
BloodNet) in order to involve a larger number of patients in
clinical trial for new therapeutic approaches. A dedicated
educational program for family doctors is needed to properly
recognize and manage these new patients.
Promote actions for strengthening more dedicated EU(5)
programs for grants on preclinical and clinical studies on
b-thalassemia.
Networking with patient associations: Patient associations
play a crucial role in present and future actions of our scientiﬁc
community devoted to improve patient care and to support
research on hemoglobinopathies. The TIF has been working with
national patient associations in more than 62 countries across the
world, including 15 EU countries, for more than three decades
now. Based on the experiences, voices and opinions gathered, we
can conﬁdently state that in order to see substantial progress in
the ﬁeld of thalassemia in Europe, efforts need to focus on
dissemination of knowledge about the prevention and care of
thalassemia in the patient community. Thus, patients will become
knowledgeable and productive partners to healthcare profes-
sionals and decision-making bodies, at the national, regional, and
international levels. Up to now, the involvement of thalassemia
patients in these processes has been extremely conﬁned, especially
when compared to their counterpart peers in oncology. This
might mainly be due to the nature of the disease (i.e., that it is a
pediatric disorder, which with appropriate management has
become a chronic disease). Thus it is understandable that in the
past thalassemia patients were more focused on dealing with the
complex and varied repercussions of their disease on their life,
14. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle
(2019) 3:3 www.hemaspherejournal.comwhich in contrast to oncology patients was not acute but chronic.
This is evidently witnessed in the development for many years
now of oncology-related PROs, and the absence of hemoglobin-
opathy-speciﬁc PROs, which will contribute to the development
of services speciﬁc for patients with hemoglobinopathies.References
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